NR4A1 and breast carcinoma: This assay is applied in clinical studies for screening (e.g., serum PSA in prostate cancer), diagnosis (e.g., identifying EGFR mutation in suspected lung cancer without histology confirmation), prognosis (e.g., hormone receptor status in breast cancer), and predicting treatment response (e.g., gene signatures for immunotherapy in various tumors).